CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 526 enrolled
Drug / intervention
terbinafine +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00443820
NCT00443820Phase 3Completed

A Randomized, Double-blind, Vehicle-controlled, Multicenter, Parallel Group Study to Assess the Efficacy, Safety, and Tolerability of Topical Terbinafine Hydrogen Chloride (HCl) Formulation for 24 or 48 Weeks of Treatment in Patients With Mild to Moderate Toenail Onychomycosis

Novartis Pharmaceuticals·interventional·Posted Mar 6, 2007·Updated Apr 19, 2011

In Brief

A Phase 3 clinical trial evaluating terbinafine and Placebo for Onychomycosis. Completed, enrolled 526 participants across 23 sites in 3 countries.

Detailed Summary

This study is designed to assess the efficacy, safety and tolerability of a topical formulation of terbinafine solution applied daily in patients with toenail fungus. This trial will study patients with mild to moderate toenail fungus disease of the big toenail and their responses to two treatment durations, 24 or 48 weeks.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOnychomycosis
CountriesFrance, Germany, United States
Collaborators--

Timeline

Phase 3CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMar 6, 2007
Enrollment StartDec 1, 2006
Primary CompletionJun 1, 2008
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 19.3 years ago

Interventions

terbinafinedrug

Terbinafine hydrochloride (HCl) 10 % nail solution for onychomycosis (NSO) once daily for 48 weeks

Placebodrug

Vehicle (placebo) once daily for 48 weeks

terbinafinedrug

Terbinafine hydrochloride (HCl) 10 % Nail Solution for Onychomycosis once daily for 24 weeks

Placebodrug

Vehicle (placebo) once daily for 24 weeks